The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumorenal syndrome (w/wo ANCAs)
Publications
Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10 Years of Hydralazine Use.
Cureus 2021 Oct;13;e18974 — 2021 Oct — e18974
Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Current cardiology reviews 2020 May 17;; — 2020 May 17
Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report.
Journal of medical case reports 2020 Apr 15;14;47 — 2020 Apr 15 — 47
Hereditary afibrinogenemia and pulmonary-renal hydralazine-induced vasculitis.
Proceedings (Baylor University. Medical Center) 2019 Jul;32;397-398 — 2019 Jul — 397-398
Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation.
International urology and nephrology 2012 Dec;44;1907-9 — 2012 Dec — 1907-9
Hydralazine-induced pulmonary-renal syndrome: a case report.
American journal of therapeutics 2012 Jul;19;e136-8 — 2012 Jul — e136-8
Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis.
Modern rheumatology 2009;19;338-47 — 2009 — 338-47